Evidence map›Paper›PMID 42253993›Full record

ReviewFrontiers in immunology2026

Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage.

Dan Yi, Rong Yang, Yue Guo, Hua Zhou, Junjun Luan

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dan YiDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Rong YangDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Yue GuoDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Hua ZhouDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.
Junjun LuanDepartment of Nephrology, Shengjing Hospital of China Medical University, Shenyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) is a common clinical syndrome characterized by substantial etiologic heterogeneity, whose pathophysiology encompasses inflammatory amplification, microcirculatory dysfunction, tubular injury, and maladaptive repair. Evidence from preclinical models and clinical samples indicates that dysregulated complement activation represents a potential convergent mechanism of injury in multiple forms of AKI, although its relative contribution varies across etiologies. Experimental models support mechanistic and pathogenic roles for complement activation, whereas clinical evidence in many AKI settings remains largely associative, suggesting a contributory rather than universally causal role. Diverse insults, including ischemia-reperfusion injury, nephrotoxins, and sepsis, can initiate complement activation, which converges on C3 and C5, fueling inflammatory escalation and tissue injury. In addition to cytotoxicity mediated by the terminal pathway, the complement system participates in the initiation, progression, and outcome of injury by orchestrating endothelial activation, leukocyte recruitment, tubular epithelial stress, and innate immune amplification. Concurrently, dysregulation of complement regulatory proteins, persistent activation of the C5a/C5aR axis, and crosstalk with Toll-like receptor signaling and neutrophil extracellular trap (NET) formation further amplify the damaging effects, thereby exacerbating AKI progression. Moreover, complement activation exhibits pronounced spatiotemporal heterogeneity, with its pathogenic effects shaped by the renal compartment, injury stage, and persistence of activation. This review summarizes the dynamic regulatory network of complement activation and its pathogenic mechanisms across diverse AKI etiologies, providing an integrative framework for biomarker-guided stratification and precision therapy in AKI.

Indexed as

Acute Kidney InjuryComplement ActivationComplement System ProteinsKidneyAnimalsComplement C5aHumansReceptor, Anaphylatoxin C5aReperfusion InjurySignal TransductionComplement C5aComplement System ProteinsReceptor, Anaphylatoxin C5aacute kidney injuryC3/C5 axiscomplement systemischemia-reperfusion injurysepsis-associated AKItubular injury

Identifiers

PMID42253993
PMCPMC13236535

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.